SCHEMBL5480288

SCHEMBL5480288

CC(=O)Oc1ccc(C2(c3ccc(OC(C)=O)cc3)C(=O)Nc3c2nc(Cl)n3C)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.48
LMNA P02545 2/20 0.35
GLA P06280 3/20 0.35
ALDH1A1 P00352 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
KIF11 P52732 1/20 0.34
RAB9A P51151 5/20 0.33
HSD17B10 Q99714 3/20 0.33
NPSR1 Q6W5P4 2/20 0.33
HPGD P15428 2/20 0.33
HTT P42858 2/20 0.33
TP53 P04637 1/20 0.33
MAPK1 P28482 1/20 0.33
CACNA1B Q00975 1/20 0.33
APBA1 Q02410 1/20 0.33
ATM Q13315 1/20 0.33
POLB P06746 4/20 0.33
PKM P14618 1/20 0.33
NPC1 O15118 4/20 0.32
KDM4E B2RXH2 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5482013 0.80 CYP19A1 (0.34) ALDH1A1RAB9AHSD17B10TP53PKM
SCHEMBL5482321 0.73 MAPT (0.60) MAPTLMNAGLAALDH1A1SMN1; SMN2
SCHEMBL5486659 0.71 MAPT (0.48) MAPTLMNAGLAALDH1A1SMN1; SMN2
SCHEMBL5474442 0.68 MAPT (0.56) MAPTLMNAGLAALDH1A1SMN1; SMN2
SCHEMBL5483571 0.66 MAPT (0.56) MAPTLMNAGLAALDH1A1SMN1; SMN2
SCHEMBL5482736 0.66 MAPT (0.56) MAPTLMNAGLAALDH1A1SMN1; SMN2
SCHEMBL5482053 0.66 MAPT (0.56) MAPTLMNAGLAALDH1A1SMN1; SMN2
Oxyphenisatin Acetate SCHEMBL29737232 0.65 MAPT (1.00) MAPTLMNAALDH1A1SMN1; SMN2NPSR1
Oxyphenisatin Acetate SCHEMBL7528210 0.65 MAPT (1.00) MAPTLMNAALDH1A1SMN1; SMN2NPSR1
Oxyphenisatin Acetate SCHEMBL555117 0.65 MAPT (1.00) MAPTLMNAALDH1A1SMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 MAPT 1785/4885LMNA 3104/4885GLA 2421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.